Karolinska Institutet
Stockholm, 113 26, Sweden
NCT Number: NCT06493097
This study aims at testing the effect and feasibility of a new treatment strategy - hypnotherapy mediated with audio files - for children and adolescents with disorders of gut-brain-interaction (DGBI) in Sweden. The treatment protocol has been used and studied in Netherlands, but the investigators have translated and formed it to suit the Swedish population. This study is a feasibility study that is followed by a large RCT to compare different psychological treatment options for this patient group.
If hypnotherapy mediated via audio files proves to be effective and feasible for this patient group, it would mean:
1. An exponential increase in the availability of evidence-based treatments. The hypnotherapy treatment is markedly easier to distribute than e.g. cognitive behavior therapy (CBT) which requires chat contact with a psychologist and is made available regardless of where in Sweden the family lives. In addition to shortened waiting times for patients, this would decrease the pressure in somatic care. 2. Possibility to offer tailored treatments. No treatment works for everyone. It is reasonable to assume that treatments with such different focuses as hypnotherapy and exposure-based CBT may be differently effective for different patients. A new treatment option can help a larger proportion of patients. 3. A more cost-effective treatment. Gut-directed hypnotherapy with audio files is a very inexpensive treatment, which would likely result in significant cost savings for this patient population.
Looking for future studies?
Notify Me8 year–17 year
All sexes
Interventional
Not applicable
Stockholm, 113 26, Sweden
Hypnotherapy has shown promising results in international studies for treatment of DGBI. Gut-directed hypnotherapy for children is based on relaxation and imagery and sensation exercises with a focus on gastrointestinal symptoms ("directed daydreams", which both divert and provide a pleasant feeling in the body, which the child can use when the symptoms come). The aim is to both improve awareness of and increase control over the symptoms. Hypnotherapy is a safe treatment that has been shown to have minimal side effects. The research group in the Netherlands with whom investigators collaborate in this project has shown a significantly better effect in short and long term with hypnotherapy than with conventional medical treatment for children and adolescents with DGBI. Hypnotherapy via home-based self-exercises with audio files is proven as effective as individual therapy performed face-to-face by a therapist.
Preliminary results/ backround work: Collaboration with the Dutch group started, the treatment manual for gut-directed hypnotherapy has been translated into Swedish and has undergone cultural validation by experienced child psychologists and has been recorded in audiobook quality. The study website (where the families have access to the treatments and measure the outcomes) has been created. Comprehensive patient information material has been created about DGBI and hypnotherapy, which consists of both texts, films, and audio to reach all patient types (Fig 1a-b). The pilot study is ongoing since Sep 2023.
Aim: To test the practical aspects concerning patient recruitment, information about treatment, the treatment itself, measurement of outcome, required power for the main outcome. The lessons learned will help investigators to fine-tune the protocol and give the planned large RCT optimal conditions.
Study population: 30 patients (8-17 years, of which approximately half are 13-17 years) from Sachsska Children's Hospital's Gastrointestinal Clinic and Pediatric and Adolescent Medical Clinics in Stockholm, who are diagnosed with DGBI following Rome IV criteria. Before inclusion, the families meet with a study physician and a study nurse for an assessment of inclusion and exclusion criteria, for information about the study, and review of treatment principles.
Exposure: Gut-directed hypnotherapy exercises 5 times/week, for 12 weeks, delivered via audio files on the study's website (files can also be downloaded to mobile phone).
Outcome: At the beginning and end of the treatment and every third week during the treatment, the patients and parents will fill in self-assessments in the form of internationally validated questionnaires for symptom severity, quality of life, school absence etc, via an internet platform with identification control (which we have worked with in many previous projects). Improvement by >30% on the primary outcome measure is defined as clinically significant, based on international recommendations.
Power: In several previous pilot studies, 30 patients have been sufficient to obtain meaningfully tight confidence intervals for the outcome measures and to be able to conclude for future RCTs. However, no formal power analysis is relevant without a comparison group.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
5 audio files 10-15 min each, min 5 times a week for 12 weeks
Time frame: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
Short questionnaire gastrointestinal symptom scale. Minimum value 0, maximum value 100, higher score means better outcome.
Time frame: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
FACES pain scale. Minimum value 0, maximum value 10, higher score means worse outcome.
Time frame: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
PAS pediatric stress questionnare. Minimum value 0, maximum value 44, higher score means worse outcome.
Time frame: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
BRQ-C questionnare. Minimum value 11, maximum value 77, higher score means worse outcome.
Time frame: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
Visceral sensitivity index short scale. Minimum value 0, maximum value 35, higher score means worse outcome.
Time frame: Week 0 (pre) and 12 (post) of treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
Peds-QL- QOL. Minimum value 0, maximum value 100, higher score means better outcome.
Time frame: Week 12 (post) treatment. The post-treatment measurement must be finished within 2 weeks from end of treatment.
SAQ. Minimum value 0, maximum value 7, higher score means better outcome.
Karolinska Institutet
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04176341
Adapted Physical Activity, Chronic Pain
Grenoble, France
View Trial DetailsNCT05143203
Anxiety, Anxiety Disorders
Metz, Grand Est, France
View Trial DetailsNCT03823742
Colonic Diseases, Colonic Diseases, Functional
Houston, Texas, United States
View Trial DetailsNCT06315179
Anorectal Disorder, Bile Duct Diseases
Seattle, Washington, United States
View Trial Details